• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Respiri Share Price Lifts on Positive Clinical Study (ASX:RSH)

Like 0

By Lachlann Tierney, Tuesday, 01 September 2020

The share price of medical technology company Respiri Ltd [ASX:RSH] has pushed higher today thanks to positive results from its latest clinical study. At the time of writing, RSH shares had pushed 3.23% higher to trade at 1.6 cents...

The share price of medical technology company Respiri Ltd [ASX:RSH] has pushed higher today thanks to positive results from its latest clinical study.

At the time of writing, RSH shares had pushed 3.23% higher to trade at 1.6 cents.

The RSH share price has grown exponentially after the company announced it had doubled its FY20 revenue last week.

Today’s share price rise puts RSH just shy of its 52-week high of 1.7 cents.

Wheezo successfully detects wheeze

Good news for the development of RSH’s software ‘wheezo’.

The e-health company said the latest clinical study shows a moderate agreement between their technology and physicians in detecting wheeze.

Respiri is an e-health software-as-a-service (SaaS) company that develops devices to assist in respiratory health management.

Its wheezo technology detects wheezing in breathing to provide an objective measure of airway limitation.

Wheeze is a typical symptom of asthma, COPD, and respiratory disease.

Wheezo employs machine learning to provide personalised feedback and education based on the user’s personal health data correlated with environmental factors.

RSH is part of a growing number of AI stocks focusing on healthcare.

Robot doctors: How AI is revolutionising healthcare (FREE REPORT).

In today’s announcement, RSH said their latest study pitted wheezo against the gold standard clinician-based stethoscope measurement of wheeze.

The study results from RSH’s previous algorithm showed that the wheeze rate measured by wheezo correctly detected wheeze 74% of the time and correctly detected no wheeze 83% of the time.

But when the data was reanalysed the algorithm was improved.

Results then showed wheezo correctly detected wheeze in 81% of cases and correctly detected no wheeze in 79% of cases.

When accounting for the subjectivity in physician assessment, wheezo was able to correctly detect wheeze in 89% of cases.

What does this mean for Respiri?

RSH has already announced high hopes for their proprietary technology.

In July this year the company said it is forecasting revenues of $6–8 million by the end of calendar year 2021.

A year and a half away at the time.

Given the doubling of their revenue during the previous financial year, the guidance might not be as ambitious as first thought.

Although FY20 revenue came in at $2.2 million.

Meaning, they’ll need to triple revenue before the end of next year.

What this does suggest is just how much confidence RSH has in their product.

And given the trouble one respiratory disease has caused recently, doctors and patients might be more vigilant.

But RSH isn’t the only AI stock to have made big strides recently. Another ASX-listed AI stock has doubled its share price five times since 2015. If you want to learn more then get yourself a free copy of our report, ‘The Most Exciting AI and Automation Stocks on the ASX’. Download your copy here.

Regards,

Lachlann Tierney,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney

Lachlann’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • Don’t Get Swept Up By the Herd: Bulls & Bears in an Age of Social Media
    By Charlie Ormond

    Markets have always reflected this chaotic behaviour, but today’s markets operate in an environment fundamentally transformed by social media.

  • The latest Closing Bell is available now
    By Callum Newman

    Tune in today to watch the latest Closing Bell podcast with Murray Dawes. We discuss gold, oil, real estate…plus a stock to watch. Tune in now!

  • Thorium: One Step Closer to China’s Energy Fortress
    By James Cooper

    Forget AI, the biggest breakthrough of this century will revolve around ENERGY. And the commercialisation of Thorium reactors could be at the heart. Read on to find out why China could be about to make history.

Primary Sidebar

Latest Articles

  • Don’t Get Swept Up By the Herd: Bulls & Bears in an Age of Social Media
  • The latest Closing Bell is available now
  • Thorium: One Step Closer to China’s Energy Fortress
  • The famous yield curve: buy or sell signal? You decide…
  • How Australians voted for a great wealth redistribution

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988